Scientists have discovered a powerful pain reliever that is effective in alleviating neuropathic pain, a discovery that could be instrumental in addressing the opioid abuse epidemic, one of the biggest public health challenges today.
In the study, the synthetic compound -- known as UKH-1114 -- was found effective in relieving neuropathic pain in injured mice. It was as effective as a drug widely used for pain relief called gabapentin.
The new pain drug binds to a receptor on cells throughout the central nervous system called the sigma 2 receptor.
Administering UKH-1114 on mice with nerve damage showed reduction in pain, but at a much lower dose than gabapentin (one-sixth as much) and was effective much longer (lasting for a couple of days, compared with four to six hours).
"This opens the door to having a new treatment for neuropathic pain that is not an opioid," said Stephen Martin, Professor at The University of Texas at Austin.
"And that has huge implications," Martin added, in the paper published in the journal ACS Chemical Neuroscience.
If the drug is proved to be safe, effective and non-addictive in humans, the discovery could be instrumental in addressing the opioid abuse epidemic, the researchers said.
According to the National Institute on Drug Abuse, nearly two million people in the US suffer from addiction to prescription opioid pain relievers.
Opioids also often require increased dosing to maintain efficacy.
Alternatives to opioids have their own drawbacks -- for example, gabapentin (sold as Neurontin) can cause cognitive impairment in certain individuals, the researchers said.
Neuropathic pain, or chronic pain, is caused when nerves in the central nervous system are damaged. Among other things, it can result from chemotherapy, diabetes and injuries to the brain or spinal cord.
--IANS
rt/him/mr
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
